Cereno Scientific Dirección

Dirección controles de criterios 0/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Sten Sorensen

Chief Executive Officer (CEO)

SEK 7.3m

Compensación total

Porcentaje del salario del CEO	38.0%
Permanencia del CEO	9.8yrs
Participación del CEO	n/a
Permanencia media de la dirección	1.9yrs
Promedio de permanencia en la Junta Directiva	1.4yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Sten Sorensen en comparación con los beneficios de Cereno Scientific?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2024	n/a	n/a	-SEK 81m
Jun 30 2024	n/a	n/a	-SEK 69m
Mar 31 2024	n/a	n/a	-SEK 59m
Dec 31 2023	SEK 7m	SEK 3m	-SEK 48m
Sep 30 2023	n/a	n/a	-SEK 35m
Jun 30 2023	n/a	n/a	-SEK 31m
Mar 31 2023	n/a	n/a	-SEK 27m
Dec 31 2022	SEK 2m	SEK 2m	-SEK 28m

Compensación vs. Mercado: La compensación total de Sten($USD671.66K) está por encima de la media de empresas de tamaño similar en el mercado Swedish ($USD236.10K).

Compensación vs. Ingresos: La compensación de Sten ha aumentado mientras la empresa no es rentable.

CEO

Sten Sorensen (65 yo)

9.8yrs

Permanencia

SEK 7,347,000

Compensación

Mr. Sten R. Sorensen serves as Director of Cereno Scientific AB (publ) since April 16, 2024. He serves as Director of SynAct Pharma AB since March 20, 2024. He serves as the Chief Executive Officer at Cere...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Sten Sorensen	CEO & Director	9.8yrs	SEK 7.35m	sin datos
Jonas Saljo	Chief Intellectual Property Officer	5.4yrs	SEK 893.00k	sin datos
Eva Jagenheim	Chief Financial Officer	1.3yrs	sin datos	sin datos
Bjorn Dahlof	Chief Scientific Officer	1.9yrs	SEK 96.00k	0.27% SEK 3.8m
Henrik Westdahl	Director of Communications & IR	less than a year	sin datos	sin datos
Tove Bergenholt	Director of Communications & IR (currently on parental leave)	less than a year	sin datos	sin datos
Fredrik Frick	Head of Clinical Operations	2.5yrs	sin datos	sin datos
Nicholas Oakes	Head of Preclinical Development	2.3yrs	sin datos	sin datos
Rahul Agrawal	Chief Medical Officer & Head of R&D	less than a year	sin datos	sin datos

1.9yrs

Permanencia media

58yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de CRNO B no se considera experimentado ( 1.9 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Sten Sorensen	CEO & Director	less than a year	SEK 7.35m	sin datos
Bertram Pitt	Chairman of Scientific Advisory Board	no data	sin datos	sin datos
Deepak Bhatt	Member of Scientific Advisory Board	no data	sin datos	sin datos
Jeppe Ovlesen	Director	less than a year	SEK 18.00k	sin datos
Gordon Williams	Member of Scientific Advisory Board	no data	sin datos	sin datos
Anders Svensson	Director	6.1yrs	SEK 917.00k	0.13% SEK 1.9m
Gunnar Olsson	Director & Member of Scientific Advisory Board	less than a year	sin datos	sin datos
Raymond Benza	Member of Scientific Advisory Board	3.8yrs	sin datos	sin datos
Faiez Zannad	Member of Scientific Advisory Board	no data	sin datos	sin datos
Joakim Soderstrom	Chairperson	1.8yrs	SEK 2.61m	0.55% SEK 7.9m

1.4yrs

Permanencia media

63.5yo

Promedio de edad

Junta con experiencia: La junta directiva de CRNO B no se considera experimentada (1.4 años de permanencia promedio), lo que sugiere una nueva junta directiva.

Cereno Scientific Dirección

Dirección controles de criterios 0/4

Información clave

Actualizaciones recientes de la dirección

Chairperson recently bought kr75k worth of stock

Cereno Scientific AB Announces Changes in the Nomination Committee's Composition for the Annual General Meeting 2025

No independent directors

Cereno Scientific AB (publ), Annual General Meeting, Jun 17, 2025

Cereno Scientific AB (Publ) Announces Nomination Committee Appointments Ahead of Annual General Meeting 2025

Cereno Scientific AB (publ), Annual General Meeting, Apr 16, 2024

Recent updates

Chairperson recently bought kr75k worth of stock

Third quarter 2024 earnings released

Cereno Scientific Announces Initiation of Multiple Ascending Dose (MAD) Part of Phase I Trial of the Novel HDAC Inhibitor CS014

Cereno Scientific AB (publ) to Report Q2, 2025 Results on Aug 27, 2025

Cereno Scientific AB (publ) Selects Rare Disease Idiopathic Pulmonary Fibrosis as the Initial Target Indication for Novel HDACi CS014

Is Cereno Scientific (STO:CRNO B) Using Debt Sensibly?

Cereno Scientific AB (publ) Announces New Preclinical Data Demonstrates Dose Dependent Positive Impact on Reversal of Pulmonary Vascular Remodeling

Cereno Scientific AB Announces Changes in the Nomination Committee's Composition for the Annual General Meeting 2025

No independent directors

Cereno Scientific AB Announces New Preclinical Data for Cereno Scientific's Novel IP Receptor Agonist CS585 Presented at ESC Congress 2024

Cereno Scientific Receives Orphan Medicinal Product Designation in the Eu for Cs1 in Rare Disease Pulmonary Arterial Hypertension

Cereno Scientific AB (publ), Annual General Meeting, Jun 17, 2025

Cereno Scientific Expands Patent Protection for PAH Drug Candidate CS1's Third Patent Family in Brazil

First Subject Dosed in Cereno Scientifics First-In-Human Phase I Trial of Novel Hdac Inhibitor Cs014

Cereno Scientific Receives Approval from, EMA to Initiate First-In-Human Phase I Trial with Novel Epigenetic HDAC Inhibitor, CS014

New major risk - Financial position

Cereno Scientific AB (publ) to Report Q1, 2025 Results on May 22, 2025

Cereno Scientific AB (Publ) Announces Nomination Committee Appointments Ahead of Annual General Meeting 2025

Cereno Scientific AB (publ), Annual General Meeting, Apr 16, 2024

Cereno Scientific AB (Publ) Approves Election of New Directors

Cereno Scientific AB Submits Clinical Trial Application (CTA) for First-In-Human Phase I Study with Novel Epigenetic HDACi Drug Candidate CS014

Full year 2023 earnings released: kr0.21 loss per share (vs kr0.20 loss in FY 2022)

Cereno Scientific Announces A Study Protocol Presented for the FDA Approved Expanded Access Program for CS1 in PAH

Director exercised options to buy kr1.0m worth of stock.

Cereno Scientific Appoints Don De Bethizy as Board of Directors

Cereno Scientific Publishes Update and Study Protocol for the FDA Approved Expanded Access Program for CS1 in PAH

Cereno Scientific Reports One New Patient Enrolled, One Additional Patient Randomized, and One Additional Patient Completed in the Phase II Study of CS1 in PAH

Full year 2023 earnings released: kr0.21 loss per share (vs kr0.20 loss in FY 2022)

Cereno Scientific Reports Progress of Expanded Access Program and Announces Timeline Adjustment in the Phase II Study of CS1 in PAH

New minor risk - Market cap size

Cereno Scientific AB Appoints Rahul Agrawal as Chief Medical Officer and Head of R&D

Cereno Scientific AB (publ) Appoints Megha Ranjan as Project Director to Strengthen Business Capabilities

Cereno Scientific AB Appoints Julia Fransson as Director of Business Development

Cereno Scientific Receives Expanded Access by the FDA to Drug Candidate CS1 for Rare Disease Pulmonary Arial Hypertension

Cereno Scientific Strengthens R&D with Recruitment of Tatiane Abreu Dall'Agnol as Medical Director

Cereno Scientific AB Confirms New Clinic Activated in the Phase II Study of Drug Candidate CS1 in Rare Disease PAH

Cereno Scientific AB (publ) to Report Q3, 2024 Results on Nov 21, 2024

Cereno Scientific's Novel HDACi CS014 Has Potential to Become an Effective Antithrombotic Therapy in Patients with A High Risk of Thrombotic Events as Presented at the ASH Meeting

Cereno Scientific Announces New Preclinical Data Concludes That Drug Candidate CS585

Cereno Scientific Completes Preclinical Safety Program for Innovative Drug Candidate CS014 Targeting Thrombosis Prevention and Reaches A Major Preparatory Milestone Towards the Phase I Study

Cereno Scientific Obtains First Patent in India for Drug Candidate Cs1 Through Its Third Patent Family

Cereno Scientific AB (Publ) Move to Request “Compassionate Use” of CS1 for Treatment of Patients with Rare Disease PAH

New major risk - Financial position

Third quarter 2023 earnings released

Cereno Scientific Reports Significant Progress and A Time Time Adjustment in the Phase II Study of CS1 in Rare Disease PAH

Cereno Scientific AB (publ) Appoints Jeppe Øvlesen as a New Board Member

Cereno Scientific AB (Publ) Reports Positive Results from the Data Quality Control Review Initiative in the Phase II Study of CS1 in Rare Disease Pul Arterial Hypertension (PAH)

Cereno Scientific Announces Appointments to the Nomination Committee Ahead of the Annual General Meeting 2024

New major risk - Shareholder dilution

Will Cereno Scientific (STO:CRNO B) Spend Its Cash Wisely?

Chief Medical Officer recently bought kr208k worth of stock

Second quarter 2023 earnings released

Cereno Scientific to Open Two New Clinics to Complete Patient Recruitment in the Phase II Study of CS1 in Pah

Cereno Scientific AB (Publ) Appoints Eva Jagenheim as Chief Financial Officer

Cereno Scientific Reports Positive Data from Patient Case Study

Chairperson recently bought kr804k worth of stock

Cereno Scientific Reports an Investigator-Initiated Patient Case Study from the Ongoing Phase II Study of CS1 in PAH

Cereno Scientific AB (publ), Annual General Meeting, Jun 03, 2024

Cereno Scientific Shares Progress Update in the Phase II Study with Drug Candidate CS1 in the Rare Disease PAH

Cereno Scientific's Phase II Study in the Rare Disease PAH Reports Two Patients Successfully Completed the Treatment Period with Drug Candidate CS1

Full year 2022 earnings released: kr0.20 loss per share (vs kr0.15 loss in FY 2021)

We're Keeping An Eye On Cereno Scientific's (NGM:CRNO B) Cash Burn Rate

Full year 2022 earnings released: kr0.26 loss per share (vs kr0.15 loss in FY 2021)

Cereno Scientific AB (publ) Reports Progress with CS1 Phase II Study in Pulmonary Arterial Hypertension

Cereno Scientific AB (publ) to Report Nine Months, 2023 Results on Nov 17, 2023

Cereno Scientific AB (Publ) Appoints Etienne Adriansen to Chief Business Officer, as of March 1, 2023

Cereno Scientific Announces Changes in the Executive Management Team

Cereno Scientific Reports Six Activated Clinical Sites and Updated Timeline in the Phase II Study in PAH with Drug Candidate CS1

Cereno Scientific AB (Publ) Announces Appointment of Nomination Committee